Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000586514 | SCV000695732 | pathogenic | Fabry disease | 2017-01-25 | criteria provided, single submitter | clinical testing | Variant summary: The GLA c.1225C>G (p.Pro409Ala) variant involves the alteration of a conserved nucleotide. 5/5 in silico tools predict a damaging outcome for this variant. This variant is absent in 87694 control chromosomes, but has been reported in affected individuals in the literature. Additionally, alpha-Gal activity was reported as <10% in HEK-293 cells bearing this mutation. Taken together, this variant is classified as pathogenic. |